These analysts have also projected a Low Estimate of $0.32/share and a High Estimate of $0.38/share. ValuEngine upgraded Sucampo Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, December 7th. initiated coverage on Sucampo Pharmaceuticals in a report on Wednesday, November 15th. The biopharmaceutical company reported $0.28 EPS for the quarter, beating the Zacks' consensus estimate of $0.26 by $0.02. The company had revenue of $61.27 million for the quarter, compared to analysts' expectations of $58.05 million.
What to Expect From Sucampo Pharmaceuticals, Inc.
Several other equities research analysts have also recently weighed in on SCMP.
Sucampo Pharmaceuticals, Inc. (SCMP) stock is now trading 61.91% away from its average-price of 200 days while it maintained a distance of 37.32% from its 50 Days Moving Average and 7.43% compared with the 20 Day Moving Average.
Sucampo Pharmaceuticals, Inc. has distance from 20-day Simple Moving Average (SMA20) of 6.35%, Distance from 50-Day Simple Moving Average of SMA50 percent and Distance from 200-Day Simple Moving Average of 59.34%. They issued a "buy" rating and a $14.00 price objective for the company.
When we look at the Analyst Recommendations of the stock, the company has 2.71 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell.
Allegheny Technologies Inc. (ATI) analysts on average have given a price target of $25.15 on ATI stock.
David Harbour Crashed Someone's Yearbook Photos, Just Like He Promised
When I originally retweeted it, I did it because I really wanted to see if Harbour would stick to it, and he did. Fregoso exceeded the requirement and ranked in over 29,000 retweets .
Shares of Sucampo Pharmaceuticals (SCMP) traded up $0.10 during trading on Monday, hitting $18.60. The company has market cap of $847.29 million. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46. Its 52-week high and low range is between $18.75 and $9.3. Finally, SGYP's beta of 1.24 indicates that the stock has an above average level of market risk.
Institutional investors have recently bought and sold shares of the business. Krensavage Asset Management LLC now owns 2,819,708 shares of the biopharmaceutical company's stock valued at $29,607,000 after purchasing an additional 16,570 shares in the last quarter.
Investors who purchased shares of Sucampo Pharmaceuticals, Inc.
The market capitalization (Stock Price Multiply by Total Number of Outstanding Shares) for the company is reported at $21.62B. Finally, State Board of Administration of Florida Retirement System raised its position in Sucampo Pharmaceuticals by 33.0% in the 3rd quarter. Royce & Associates LP now owns 1,171,731 shares of the biopharmaceutical company's stock worth $13,826,000 after acquiring an additional 103,808 shares during the last quarter. Smith Asset Management Group LP increased its stake in shares of Sucampo Pharmaceuticals by 2.1% in the third quarter. The company's institutional ownership is monitored at 74 percent. It fall, as 21 investors sold CHRS shares while 23 reduced holdings. To cut down amount of noise on price chart, shares of firm has 20 days moving average price of 6.66% from last close price of 18.55 and act as support or resistance of price limit. Following the completion of the transaction, the insider now directly owns 52,023 shares in the company, valued at $858,379.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
TRADEMARK VIOLATION WARNING: This report was first posted by [[site]] and is the property of of [[site]]. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of USA & worldwide copyright & trademark legislation. The legal version of this story can be accessed at https://www.truebluetribune.com/2018/01/12/fy2019-eps-estimates-for-sucampo-pharmaceuticals-inc-lifted-by-leerink-swann-scmp.html.
Rockville, MD based Sucampo Pharmaceuticals, Inc.is a biopharmaceutical company. It operates through development and commercialization of pharmaceutical products segment. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders.